[CD25-positivity and efficacy of roncoleukin in complex treatment of patients with gastroduodenal ulcers complicated by hemorrhage].
In 72 patients, suffering gastroduodenal ulcer disease recombinant interleukin-2 (LL-2) Roncoleukin ("Biotech", Russia) was applied in complex of treatment. The main populations of immunocytes, containing cellular-tissue receptor IL-2 CD25, were investigated in specimen from various zones of gastroduodenal mucosa and peripheral blood. There was established the trustworthy hyperexpression of CD25 in patients while gastrointestinal hemorrhage. Roncoleukin inclusion into the complex of treatment of patients have promoted more effective normalization of affinity of various immunocytes type towards IL-2 receptors, clinical signs occurrence of the disease elimination and the ulcer defect epithelization acceleration.
K A
KA
Eĭvazova
I A
IA
Gasanov
D000328:Adult; D000368:Aged; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D005753:Gastric Mucosa / Q000276:immunology; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage / Q000627:therapeutic use*; D007275:Injections, Intravenous; D007376:Interleukin-2 / Q000008:administration & dosage / Q000627:therapeutic use*; D053645:Interleukin-2 Receptor alpha Subunit / Q000276:immunology*; D007413:Intestinal Mucosa / Q000276:immunology; D008297:Male; D008875:Middle Aged; D010437:Peptic Ulcer / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D010438:Peptic Ulcer Hemorrhage / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D016896:Treatment Outcome
C508017:IL2RA protein, human; D007155:Immunologic Factors; D007376:Interleukin-2; D053645:Interleukin-2 Receptor alpha Subunit